Figure 11.5.
HER2/c-erbB2 immunostain of breast carcinoma.
Strong plasma membrane immunoreactivity for c-erbB2/HER2 is noted, guiding use of either anti-HER2 antibody or HER2 kinase inhibitor therapy.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.